More on this trial News story |  Tildrakizumab shows promise for PsA Clinical trial commentary | LISTEN: Tildrakizumab trial lead investigator Philip Mease outlines the results External link | Conference abstract External link | ClinicalTrials.gov registration page ​​​​​​​

This phase IIb placebo-controlled trial aims to investigate the safety and efficacy profiles of the anti-interleukin-23P19 monoclonal antibody tildrakizumab in patients with active psoriatic arthritis. Wednesday 12 June: 16:15–17:45 (Abstract LB0002)

Phase IIb trial results reported at the EULAR 2019 congress in Madrid, Spain, suggest that tildrakizumab may be a promising treatment option for people with psoriatic arthritis.

News story |  Tildrakizumab shows promise for PsA Researcher comment | LISTEN: Philip Mease outlines the results

Lead investigator Philip Mease outlines the results of a phase IIb trial supporting further development of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for the treatment of psoriatic arthritis (8:45).

She adds that the IL-23 specific inhibitors guselkumab and tildrakizumab, which are currently approved for the treatment of psoriasis, along with the IL-23 inhibitors risankizumab and mirikizumab that are presently under investigation, “work very well for skin and their effect on the joints is currently being evaluated.”

Wednesday 12th June, 16:15–17:45, Hall 6, IFEMA – Feria de Madrid, Madrid, Spain. Chairs –  John Isaacs and Thomas Dörner What to choose: a second TNFI or an alternative class of biologic for patients with JIA who have failed their first TNF.  Lianne Kearsley-Fleet Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. Bernard Combe Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Oliver Distler MiR-34A is a potential therapeutic target in osteoarthritis. Mohit Kapooor A systematic review and meta-analysis assessing gastrointestinal, liver, renal and cardiovascular adverse events of paracetamol. Jaspreet Kaur Less is more: analysing the impact of repeated antinuclear antibody testing. Ai Li Yeo Predicting severe infection in repeat cycles of rituximab and effects of hypogammaglobulinaemia for the treatment of rheumatic and musculoskeletal diseases.  Md Yuzaiful Md Yusof Do MRI-detected erosions in patients with clinically suspect arthralgia predict progression to rheumatoid arthritis? A longitudinal study. Fenne Wouters Randomised, double-blind, placebo-controlled, multiple-dose, Phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis. Philip Mease

Fenne Wouters Randomised, double-blind, placebo-controlled, multiple-dose, Phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis.